115 related articles for article (PubMed ID: 22440501)
1. Treatment paradigms for the superficial femoral artery: are they a-changin?
Scheinert D
JACC Cardiovasc Interv; 2012 Mar; 5(3):339-40. PubMed ID: 22440501
[No Abstract] [Full Text] [Related]
2. Drug-eluting balloons: are they the magic bullet?
Varcoe RL
J Endovasc Ther; 2012 Oct; 19(5):581-4. PubMed ID: 23046321
[No Abstract] [Full Text] [Related]
3. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry.
Micari A; Cioppa A; Vadalà G; Castriota F; Liso A; Marchese A; Grattoni C; Pantaleo P; Cremonesi A; Rubino P; Biamino G
JACC Cardiovasc Interv; 2012 Mar; 5(3):331-8. PubMed ID: 22440500
[TBL] [Abstract][Full Text] [Related]
4. Drug-coated balloons--the importance of packing and dosing antiproliferative drugs.
Hehrlein C
Catheter Cardiovasc Interv; 2015 Aug; 86(2):287-8. PubMed ID: 26198065
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous revascularization for peripheral arterial disease: paclitaxel saves the day.
Mahmud E
JACC Cardiovasc Interv; 2013 Mar; 6(3):290-2. PubMed ID: 23517841
[No Abstract] [Full Text] [Related]
6. Standard balloon angioplasty versus angioplasty with paclitaxel-eluting balloons for femoropopliteal artery stenosis.
Ju MH; Rodríguez HE
J Cardiovasc Surg (Torino); 2012 Aug; 53(4):459-63. PubMed ID: 22854525
[TBL] [Abstract][Full Text] [Related]
7. The THUNDER trial results: clearing the way or ushering the storm?
Jaff MR
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):109-10. PubMed ID: 25616823
[No Abstract] [Full Text] [Related]
8. Commentary: treatment of femoropopliteal in-stent restenosis for patients with diabetes: do we have an answer to the DEBATE?
Armstrong EJ; Laird JR
J Endovasc Ther; 2014 Feb; 21(1):9-11. PubMed ID: 24502478
[No Abstract] [Full Text] [Related]
9. A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results.
Micari A; Cioppa A; Vadalà G; Stabile E; Castriota F; Pantaleo P; Grattoni C; Cremonesi A; Marchese A; Rubino P; Biamino G
EuroIntervention; 2011 May; 7 Suppl K():K77-82. PubMed ID: 22027734
[TBL] [Abstract][Full Text] [Related]
10. Commentary: how do we deal with dissection after angioplasty?
Fanelli F; Cannavale A; Gazzetti M; D'Adamo A
J Endovasc Ther; 2013 Dec; 20(6):801-4. PubMed ID: 24325696
[No Abstract] [Full Text] [Related]
11. Innovative technologies for SFA occlusions: drug coated balloons in SFA lesions.
Minar E; Schillinger M
J Cardiovasc Surg (Torino); 2012 Aug; 53(4):481-6. PubMed ID: 22854528
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
Teichgräber U; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Thieme M; Blessing E; Treitl M; Lichtenberg M; von Flotow P; Vogel B; Werk M; Riambau V; Wienke A; Lehmann T; Sixt S
Trials; 2016 Oct; 17(1):528. PubMed ID: 27793175
[TBL] [Abstract][Full Text] [Related]
14. Commentary: aligning incentives of payer, facility, and provider: the lynchpin of providing more cost-effective care.
Sternbergh WC
J Endovasc Ther; 2013 Dec; 20(6):826-7. PubMed ID: 24325700
[No Abstract] [Full Text] [Related]
15. Commentary: comparative effectiveness of paclitaxel-based femoropopliteal interventions.
Armstrong EJ
J Endovasc Ther; 2014 Jun; 21(3):369-72. PubMed ID: 24915583
[No Abstract] [Full Text] [Related]
16. Drug coated ballons for femoro-popliteal interventions.
Tamburrini L; Vosseler M; Espinola-Klein C
Vasa; 2018 Jan; 47(1):68-69. PubMed ID: 29281955
[No Abstract] [Full Text] [Related]
17. Paclitaxel density and clinical efficacy of drug-coated balloon angioplasty for femoropopliteal artery disease: meta-analysis and adjusted indirect comparison of 20 randomised trials.
Cassese S; Ndrepepa G; Fusaro M; Kufner S; Xhepa E; Fusaro M
EuroIntervention; 2019 Aug; 15(6):e560-e562. PubMed ID: 30277463
[No Abstract] [Full Text] [Related]
18. [Efficacy of balloon catheters with antiproliferative cover in patients with impairment of arteries of femoral-popliteal segment].
Pityk AI
Klin Khir; 2015 Feb; (2):49-51. PubMed ID: 25985697
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Mehrotra S; Paramasivam G; Mishra S
Curr Cardiol Rep; 2017 Feb; 19(2):10. PubMed ID: 28185166
[TBL] [Abstract][Full Text] [Related]
20. Missing the Forest for the Trees?: Drug-Eluting Balloon Treatment for Infrapopliteal Disease.
Tsai TT
JACC Cardiovasc Interv; 2015 Oct; 8(12):1623-5. PubMed ID: 26493254
[No Abstract] [Full Text] [Related]
[Next] [New Search]
